Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China

ICP-B794 has demonstrated superior anti-tumor activity in animal models, and exhibited significant tumor-killing effects even in large tumors.
October 29, 2025 23:51 ET | Source: InnoCare Pharma

Latest Data of InnoCare's Zurletrectinib Orally Presented at SIOP 2025

Zurletrectinib demonstrated well-tolerated safety and promising antitumor activity in pediatric/adolescent patients with NTRK/ROS1-altered solid tumors.
September 07, 2025 20:30 ET | Source: InnoCare Pharma

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

InnoCare's HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with R/R MZL.
August 21, 2025 09:24 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China

The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.